"The decision by the European Commission is an important advancement for people living with IgAN in the EU", said Dr. Vinicius Gomes De Lima, Head of Global Medical Affairs at CSL Vifor.

ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /CNW/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional ...

Australian biopharma CSL has a rich history. The company, which was originally called Commonwealth Serum Laboratories, was started by the government during World War I as a means to get critical ...

CSL Vifor posted a 6% revenue growth, reaching $1.07 billion, slightly exceeding consensus expectations. CSL acquired Vifor Pharma for US$11.7 billion in August 2022, but many analysts believe the ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing ...

"Together with our partner, CSL Vifor, we look forward to people living with IgAN in Switzerland gaining access to this important medicine." Swissmedic approval was supported by results from the ...

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of ...

"Together with our partner, CSL Vifor, we look forward to people living with IgAN in Switzerland gaining access to this important medicine." Swissmedic approval was supported by results from the ...